Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 1 April 2025, 12:15 HKT/SGT
Share:
    

Source: Eisai
Eisai to Divest Rights for Pariet in China to Peak Pharma

TOKYO, Apr 1, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet® (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. Peak Pharma has commenced marketing activities, while Eisai will manage the transfer of manufacturing and marketing authorizations during atransition period.

Under the terms of the agreement, Eisai will receive RMB725 million (approximately 15.7 billion JPY1) as contractual upfront payments, as well as the rights to receive a sales milestone payment. The upfront payments have already been recorded in the third quarter of Eisai’s fiscal year ending March 31, 2025.Eisai expects no changes to its consolidated financial forecast for the fiscal year ending March 31, 2025.

Pariet is a proton pump inhibitor (PPI) discovered and developed by Eisai, approved in more than 100 countries and regions worldwide. Pariet was approved in China in 2000 and is indicated forgastrointestinal disorders including gastric ulcer, duodenal ulcer, and reflux esophagitis. With the conclusion of this agreement, Eisai believes that CBC Group’s proven 'investor-operator' approach and commitment to delivering quality healthcare to a wide range of patients will maximize the value of Pariet in China.

The agreement will enable Eisai to strategically reallocate resources to other mid-to-long-term business growth areas so as to continue to make further contributions to address the diversified needs of, andincrease the benefits provided to, patients and their families.

1 Exchange rate: 1 RMB = 21.67 JPY (as of December 31, 2024)

About CBC Group

Headquartered in Singapore, CBC Group is Asia's largest healthcare-dedicated asset management firm, with an AUMof US$9 billion. With a diversified, multi-product strategy, CBC Group is focused on platform-building, buyout, privatecredit and royalties, and real estate, across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services. We are committed to creating lasting value by integrating global innovations andtalents. Partnering with the world's top entrepreneurs and scientists, our unique “investor-operator” approach has empowered leading healthcare companies to widen access to affordable medical care, catalyse innovations, and improve efficiencies in fulfilling unmet medical needs worldwide.

For more information on CBC Group, please visit www.cbridgecap.com/. Connect with us on LinkedIn (CBC Group).

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 11:21 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 5, 2025 08:09 HKT/SGT
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 4, 2025 16:22 HKT/SGT
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 3, 2025 14:41 HKT/SGT
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 3, 2025 12:53 HKT/SGT
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Feb 28, 2025 11:31 HKT/SGT
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: